#EULAR2022
JAK inhibitors: are all promises fulfilled?
Most Physicians Prefer JAKi due to
๐น Good Efficacy
๐น Faster onset of action
๐น Better adherence (50% attrition for JAK at 4 years Compared to 2 years with TNF)
JAK inhibitors: are all promises fulfilled?
Most Physicians Prefer JAKi due to
๐น Good Efficacy
๐น Faster onset of action
๐น Better adherence (50% attrition for JAK at 4 years Compared to 2 years with TNF)
#EULAR2022
JAK inhibitors: are all promises fulfilled?
๐นEfficacy of TNFi and other bDMARDs Compared
๐นJAK perform equivalently if not better
๐นBari and Upada proven to be superior to Adalimumab/abatacept in different trials
JAK inhibitors: are all promises fulfilled?
๐นEfficacy of TNFi and other bDMARDs Compared
๐นJAK perform equivalently if not better
๐นBari and Upada proven to be superior to Adalimumab/abatacept in different trials
#EULAR2022
JAK inhibitors: are all promises fulfilled?
๐นSafety signals form observational studies only showed a high risk of HZ
๐นThings Change after Oral surveillance
๐นSTAR-RA had some similar observations
๐นAvoid in those with High CV risk
JAK inhibitors: are all promises fulfilled?
๐นSafety signals form observational studies only showed a high risk of HZ
๐นThings Change after Oral surveillance
๐นSTAR-RA had some similar observations
๐นAvoid in those with High CV risk
#EULAR2022
JAK inhibitors: are all promises fulfilled?
Simple MOA
JAK1 ๐๐ป Varied actions
JAK2 ๐๐ป Hematological proliferation
JAK3๐๐ป T-cell survival
JAK inhibitors: are all promises fulfilled?
Simple MOA
JAK1 ๐๐ป Varied actions
JAK2 ๐๐ป Hematological proliferation
JAK3๐๐ป T-cell survival
#EULAR2022
JAK inhibitors: are all promises fulfilled?
Overall
๐น Efficacy Good ๐๐ป Not curative/ remission inducing though
๐น Adherence ๐๐ป Better than bDMRDS
๐นSafety ๐๐ป CV risk and Malignancy๐ฑ with HZ
๐น Simple MOA ๐๐ป Depends on the JAK you are inhibiting
JAK inhibitors: are all promises fulfilled?
Overall
๐น Efficacy Good ๐๐ป Not curative/ remission inducing though
๐น Adherence ๐๐ป Better than bDMRDS
๐นSafety ๐๐ป CV risk and Malignancy๐ฑ with HZ
๐น Simple MOA ๐๐ป Depends on the JAK you are inhibiting
Loading suggestions...